PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $25.54 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-07-30
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $25.54M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $34.23M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $80.51M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $41.35M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $25.54M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $34.23M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $80.51M 10-K · filed 2026-02-26 |
| 2025-09-30 | $41.35M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $25.28M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $489.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.13M 10-K · filed 2025-03-06 |
| 2024-09-30 | $51.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.79M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.94M 10-Q/A · filed 2024-06-14 |
| 2023-12-31 | $3.38M 10-K/A · filed 2024-06-14 |
| 2021-12-31 | $13.97M 10-K · filed 2022-03-01 |
| 2020-12-31 | $34.43M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |